373 related articles for article (PubMed ID: 23176722)
1. Can we change the disease biology of multiple myeloma?
Borrello I
Leuk Res; 2012 Nov; 36 Suppl 1(0 1):S3-12. PubMed ID: 23176722
[TBL] [Abstract][Full Text] [Related]
2. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
5. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
6. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC; Weber DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
[TBL] [Abstract][Full Text] [Related]
7. [Aging and diseases: multiple myeloma].
Hirota Y
Nihon Rinsho; 1974 Jan; 32(1):102-12. PubMed ID: 4599023
[No Abstract] [Full Text] [Related]
8. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
9. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
10. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
de Jong MME; Kellermayer Z; Papazian N; Tahri S; Hofste Op Bruinink D; Hoogenboezem R; Sanders MA; van de Woestijne PC; Bos PK; Khandanpour C; Vermeulen J; Moreau P; van Duin M; Broijl A; Sonneveld P; Cupedo T
Nat Immunol; 2021 Jun; 22(6):769-780. PubMed ID: 34017122
[TBL] [Abstract][Full Text] [Related]
11. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.
Frenquelli M; Caridi N; Antonini E; Storti F; Viganò V; Gaviraghi M; Occhionorelli M; Bianchessi S; Bongiovanni L; Spinelli A; Marcatti M; Belloni D; Ferrero E; Karki S; Brambilla P; Martinelli-Boneschi F; Colla S; Ponzoni M; DePinho RA; Tonon G
Leukemia; 2020 Jan; 34(1):257-270. PubMed ID: 31148590
[TBL] [Abstract][Full Text] [Related]
12. Possible transmissibility of human myelomatosis in immunologically deficient mice.
Mitchell DN; Rees RJ; Salsbury AJ
Lancet; 1971 Nov; 2(7732):1009-12. PubMed ID: 4108067
[No Abstract] [Full Text] [Related]
13. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
[TBL] [Abstract][Full Text] [Related]
14. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
15. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma.
Kumar SK; Rajkumar V; Kyle RA; van Duin M; Sonneveld P; Mateos MV; Gay F; Anderson KC
Nat Rev Dis Primers; 2017 Jul; 3():17046. PubMed ID: 28726797
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.
Mondello P; Cuzzocrea S; Navarra M; Mian M
Oncotarget; 2017 Mar; 8(12):20394-20409. PubMed ID: 28099912
[TBL] [Abstract][Full Text] [Related]
18. The microenvironment and molecular biology of the multiple myeloma tumor.
Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
[TBL] [Abstract][Full Text] [Related]
19. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.
Dahlhoff J; Manz H; Steinfatt T; Delgado-Tascon J; Seebacher E; Schneider T; Wilnit A; Mokhtari Z; Tabares P; Böckle D; Rasche L; Martin Kortüm K; Lutz MB; Einsele H; Brandl A; Beilhack A
Leukemia; 2022 Mar; 36(3):790-800. PubMed ID: 34584204
[TBL] [Abstract][Full Text] [Related]
20. Adhesion molecules--The lifelines of multiple myeloma cells.
Katz BZ
Semin Cancer Biol; 2010 Jun; 20(3):186-95. PubMed ID: 20416379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
